In the last trading session, 6.88 million SELLAS Life Sciences Group Inc (NASDAQ:SLS) shares changed hands as the company’s beta touched 2.41. With the company’s per share price at $1.62 changed hands at $0.29 or 21.80% during last session, the market valuation stood at $127.30M. SLS’s last price was a discount, traded about -6.17% off its 52-week high of $1.72. The share price had its 52-week low at $0.56, which suggests the last value was 65.43% up since then. When we look at SELLAS Life Sciences Group Inc’s average trading volume, we note the 10-day average is 8.53 million shares, with the 3-month average coming to 2.38 million.
Analysts gave the SELLAS Life Sciences Group Inc (SLS) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 2 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended SLS as a Hold, 2 felt it is a Buy and 0 rated the stock as Underweight. SELLAS Life Sciences Group Inc’s EPS for the current quarter is expected to be -0.11.
SELLAS Life Sciences Group Inc (NASDAQ:SLS) trade information
Instantly SLS was in green as seen at the end of in last trading. With action 60.40%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 55.77%, with the 5-day performance at 60.40% in the green. However, in the 30-day time frame, SELLAS Life Sciences Group Inc (NASDAQ:SLS) is 63.13% up. Looking at the short shares, we see there were 8.61 million shares sold at short interest cover period of 14.07 days.
The consensus price target for the stock as assigned by Wall Street analysts is 2.8, meaning bulls need an upside of 42.14% from its current market value. According to analyst projections, SLS’s forecast low is 2.4 with 3.2 as the target high. To hit the forecast high, the stock’s price needs a -97.53% plunge from its current level, while the stock would need to soar -48.15% for it to hit the projected low.
SELLAS Life Sciences Group Inc (SLS) estimates and forecasts
Data shows that the SELLAS Life Sciences Group Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 39.66% over the past 6 months, a 57.46% in annual growth rate that is considerably higher than the industry average of 15.90%.
According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 61.44%. The 2025 estimates are for SELLAS Life Sciences Group Inc earnings to increase by 59.95%, but the outlook for the next 5-year period is at 28.98% per year.
SLS Dividends
SELLAS Life Sciences Group Inc is expected to release its next quarterly earnings report in March.
SELLAS Life Sciences Group Inc (NASDAQ:SLS)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 0.24% of SELLAS Life Sciences Group Inc shares while 7.36% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 7.38%. There are 7.36% institutions holding the SELLAS Life Sciences Group Inc stock share, with VANGUARD GROUP INC the top institutional holder. As of 2024-06-30, the company held 3.9862% of the shares, roughly 1.79 million SLS shares worth $2.13 million.
SUSQUEHANNA INTERNATIONAL GROUP, LLP holds the second largest percentage of outstanding shares, with 3.6594% or 1.64 million shares worth $1.95 million as of 2024-06-30.
Among Mutual Funds, the top two as of Sep 30, 2024 were Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund . With 1.69 shares estimated at $2.74 million under it, the former controlled 2.40% of total outstanding shares. On the other hand, Vanguard Extended Market Index Fund held about 0.71% of the shares, roughly 501.97 shares worth around $0.81 million.
